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In the last years, a growing interest has emerged toward understanding the role of adipocytokines 
in the development of cardio-metabolic complications. Five years ago, visfatin/PBEF/Nampt was 
identified as a novel adipocytokine. In the context of metabolic disorders, extracellular visfatin/
PBEF/Nampt was initially claimed as a potentially beneficial molecule due to its insulin-mimetic 
and glucose-lowering properties. Nevertheless, growing evidence has since then unveiled 
that visfatin/PBEF/Nampt may rather be a biomarker of inflammation and endothelial damage, 
and also a direct regulator of the cardiovascular system that modulates cell proliferation and 
survival, extracellular matrix, vascular reactivity, and inflammation. On one side, the blockade of 
the deleterious cardiovascular actions of visfatin/PBEF/Nampt is being regarded as a potential 
approach to prevent and treat, not only cardio-metabolic complications, but also other pathologies 
implying excessive angiogenesis. Conversely, the administration of visfatin/PBEF/Nampt has 
shown beneficial effects in different ischemic conditions. Further research is required to evaluate 
the real value of visfatin/PBEF/Nampt as a pharmacological target.
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 nicotinamide into nicotinamide mononucleotide (NMN), which 
is in turn transformed into NAD+ by nicotinamide/nicotinic acid 
mononucleotide adenylyltransferase (Nmnat) (Formentini et al., 
2009) (Figure 1). Based on these observations, visfatin is nowadays 
termed as visfatin/PBEF/Nampt.
Two different forms of visfatin/PBEF/Nampt have been identi-
fied to date. On one side, intracellular visfatin/PBEF/Nampt plays a 
central role in maintaining the activity of NAD-dependent enzymes 
and is implicated in the regulation of cellular metabolism in 
response to nutrient availability, maturation and survival (Revollo 
et al., 2004; van der Veer et al., 2005, 2007; Ho et al., 2009). On the 
other side, extracellular visfatin/PBEF/Nampt can be synthesized 
and released to the extracellular milieu, not only by adipocytes but 
also by many different cell types, where it can exert a wide range of 
actions in a paracrine or endocrine manner. Indeed, extracellular 
visfatin/PBEF/Nampt shows a slightly higher molecular weight than 
the intracellular isoform and seems to undergo post-translational 
modifications (Revollo et al., 2004, 2007).
In the context of metabolic diseases, circulating visfatin/PBEF/
Nampt levels have been found elevated in different clinical condi-
tions, such as obesity, type 2 diabetes mellitus and the metabolic 
syndrome (Fukuhara et al., 2005; Sandeep et al., 2007). However, 
as recently reviewed, there is some controversy among the differ-
ent reports studying the variation of visfatin/PBEF/Nampt levels 
in these disease states, where visfatin/PBEF/Nampt has also been 
found unmodified or even lower compared to healthy controls 
(Filippatos et al., 2010).
Although visfatin/PBEF/Nampt was initially claimed as being 
preferentially released by visceral versus subcutaneous fat (Fukuhara 
et al., 2005), this latter affirmation remains controversial (Arner, 
2006). Importantly, visfatin/PBEF/Nampt has been detected in the 
IntroductIon
The adipose tissue is nowadays considered as an active endocrine 
organ that produces a heterogeneous series of bioactive factors, 
the so-called adipocytokines. These adipocytokines can act locally 
within the adipose tissue, but they can also reach distant organs 
through the systemic circulation, where they can exert a wide range 
of biological actions, including the regulation of food intake and 
body weight, insulin sensitivity, reproduction, immunity, inflam-
mation, or vascular homeostasis (Lau et al., 2005; Guzik et al., 2006). 
Importantly, an imbalanced adipocytokine production, as observed 
in clinical metabolic conditions including obesity and type 2 diabe-
tes mellitus, has been associated with adipose tissue inflammation 
and the pathogenesis of insulin resistance, but also with chronic 
systemic inflammation and endothelial dysfunction (Karastergiou 
and Mohamed-Ali, 2010). In the last years, a growing interest has 
emerged to understand the involvement of adipocytokines as direct 
players in the development of cardiovascular complications associ-
ated to metabolic diseases.
VIsfatIn/PBEf/namPt
In 2005, Fukuhara et al. (2005) first identified visfatin as an adipocy-
tokine. The authors also described visfatin as an insulin-mimetic 
with potential beneficial effects in clinical conditions, such as diabe-
tes mellitus. However, as the glucose-lowering properties of visfatin 
were hardly reproduced, the authors later on retracted from such 
statement (Fukuhara et al., 2007). Visfatin was found to be identical 
to pre-B cell colony-enhancing factor (PBEF), a 52-kDa cytokine 
acting on early B-lineage precursor cells (Samal et al., 1994) and also 
to the enzyme nicotinamide phosphoribosyltransferase (Nampt) 
(Rongvaux et al., 2002). In vertebrates, intracellular Nampt plays 
an essential role in the biosynthesis of NAD+ by  converting 
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of matrix  metalloproteinases (MMP)-2/9, as pivotal enzymes that 
facilitate angiogenesis through the degradation of the extracellu-
lar matrix, while it decreases the levels of the tissue inhibitors of 
MMP (TIMP)-1 and 2 (Adya et al., 2008a). Finally, both monocyte 
chemottractant protein (MCP)-1 (Adya et al., 2009) and fibroblast 
growth factor (FGF)-2 (Bae et al., 2009) have also been identified 
as mediators of visfatin/PBEF/Nampt-induced angiogenesis.
Regarding intracellular signaling, several reports have shown 
that phosphatidylinositol 3-kinase (PI3K)/Akt and the mitogen-
activated protein kinases (MAPK) extracellular signal-regulated 
kinase (ERK) 1/2 mediate most of the cellular events leading to 
visfatin/PBEF/Nampt-induced endothelial cell proliferation (Kim 
et al., 2007; Adya et al., 2008a, 2009; Bae et al., 2009). Other studies 
have involved the activation of the transcription factors nuclear fac-
tor (NF)-κB (Adya et al., 2009) and signal transducer and activator 
of transcription 3 (STAT3), the latter favoring the release of inter-
leukin (IL)-6 (Kim et al., 2009). Figure 3 depicts the main cellular 
events triggered by visfatin/PBEF/Nampt leading to endothelial 
cell proliferation and migration.
Based on its pro-angiogenic properties, visfatin/PBEF/Nampt 
has been proposed as a potential therapeutic agent to improve blood 
supply in certain pathological conditions characterized by restricted 
blood flow such as macrovascular peripheral limb ischemia. On 
the other hand, visfatin/PBEF/Nampt might also be a promoter 
of dysregulated angiogenesis that is involved in clinical conditions 
such as ischemic heart disease, diabetes, or atherosclerosis and may 
therefore arise as a novel pharmacological target for treating such 
conditions. In addition, a growing interest is emerging toward 
visfatin/Nampt/PBEF as a therapeutic target for cancer treatment 
(Garten et al., 2009; Bi and Che, 2010). By inhibiting Nampt activ-
ity, the formation of new vessels that can support tumor growth 
might be restricted. In this context, two Nampt inhibitors FK866 
(or APO866) and CSH-828 are being used in clinical trials (Ravaud 
et al., 2005; Pogrebniak et al., 2006).
Vascular smooth musclE cElls
Vascular smooth muscle cell proliferation is a hallmark of the 
development of atherosclerotic lesions. Besides endothelial cells, 
visfatin/PBEF/Nampt can also act as a growth factor for vascular 
smooth muscle cells. Indeed, Wang et al. (2009) have shown that 
visfatin/PBEF/Nampt contained in the perivascular fat promotes 
DNA synthesis and cell proliferation in rat aortic smooth muscle 
perivascular fat of vessels, such as aorta or coronary artery, in both 
animal models and humans (Wang et al., 2009; Spiroglou et al., 
2010). In fact, visfatin/PBEF/Nampt is released by a wide series 
of cell types, including activated monocytes/macrophages that 
can directly interact with vascular cells (Stephens and Vidal-Puig, 
2006). These findings indicate that, besides circulating visfatin/
PBEF/Nampt, locally synthesized visfatin/PBEF/Nampt may also 
exert a relevant paracrine action in regulating the vascular func-
tion. This review will focus on the actions elicited by extracellular 
visfatin/Nampt/PBEF on the cardiovascular system (summarized 
in Figure 2), where it might become a novel therapeutic target.
Vascular cEll ProlIfEratIon
EndothElIal cElls
In the last years, visfatin/PBEF/Nampt has been identified as a 
pro-angiogenic molecule. Hence, visfatin/PBEF/Nampt concen-
tration-dependently promotes cell proliferation, migration and 
capillary-like tube formation in human umbilical vein endothe-
lial cells cultures (HUVEC) (Kim et al., 2007; Adya et al., 2008a; 
Lovren et al., 2009; Xiao et al., 2009). In vivo, visfatin/PBEF/Nampt 
promotes the formation of functional neovessels (Kim et al., 2007). 
Furthermore, the injection of a plasmid containing visfatin/PBEF/
Nampt in a mouse model of unilateral limb ischemia results in 
improved limb perfusion as compared to untreated animals 
(Lovren et al., 2009).
The proliferative effect of visfatin/PBEF/Nampt in endothelial 
cells relies, at least in part, on the synthesis and secretion of vas-
cular endothelial cell growth factor (VEGF) (Adya et al., 2008a), 
a key molecule in endothelial proliferation and neovessel forma-
tion. Visfatin/PBEF/Nampt also up-regulates the VEGF receptor 
2, which mediates the angiogenic actions of VEGF (Adya et al., 
2008a,b). An enhanced production of nitric oxide (NO), as the 
consequence of increased expression and activity of endothelial 
nitric oxide synthase (eNOS), has also been proposed to be on 
the basis of the pro-angiogenic action of visfatin/PBEF/Nampt in 
human endothelial cells (Lovren et al., 2009). Furthermore, vis-
fatin/PBEF/Nampt activates dimethylarginine dimethylaminohy-
drolase (DDAH) (Xiao et al., 2009), an enzyme that hydrolyses 
the eNOS inhibitor l-arginine analog asymmetric dimethyl-
arginine (ADMA), and upregulates VEGF expression and release 
in endothelial cells (Fiedler et al., 2009). Furthermore, visfatin/
PBEF/Nampt enhances the expression, protein levels and activity 
FigurE 1 | Nicotinamide phosphoribosyltransferase (Nampt) enzymatic 
activity. Nampt uses nicotinamide as substrate to yield nicotinamide 
mononucleotide (NMN). In a subsequent step, NMN can be transformed into 
nicotinamide adenine dinucleotide (NAD+) by nicotinamide mononucleotide 
adenylyltransferase (Nmnat). The experimental drug APO866 inhibits Nampt 
activity. ATP, adenosine triphosphate.
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 subjected to endoplasmic reticulum stress, a process associated to 
obesity and obesity-related complications (Li et al., 2008). Such an 
effect of visfatin/PBEF/Nampt is not related to Nampt activity, but 
rather involves the release of interleukin (IL)-6 by macrophages 
that in turn acts in a paracrine and/or autocrine manner to activate 
intracellular STAT3 signaling (Li et al., 2008). These data indicate 
that visfatin/PBEF/Nampt may affect the balance between mac-
rophage survival and death in obesity. By promoting macrophage 
survival, visfatin/PBEF/Nampt may contribute, not only to adipose 
tissue inflammation, but also to vascular inflammation and the 
progression of atherosclerotic lesions, as will be discussed below.
Vascular tonE and rEactIVIty
The scarce reports available to date exploring the potential direct 
actions of visfatin/PBEF/Nampt on the regulation of the vascular 
tone are contradictory. On one hand, visfatin/PBEF/Nampt has been 
claimed to stimulate the expression and activity of eNOS in endothe-
lial cells, resulting in enhanced NO production and cyclic GMP forma-
tion in human umbilical vein and coronary endothelial cells in vitro 
(Lovren et al., 2009). By favoring NO release, visfatin/PBEF/Nampt 
cell cultures through Nampt enzymatic activity. Hence, the pro-
liferative action of visfatin/PBEF/Nampt is mimicked by the final 
product of the Nampt reaction, NMN, and is abolished by the 
Nampt pharmacological blocker FK866 (or APO866) (Wang et al., 
2009). Intracellularly, the activation of ERK 1/2 and p38 MAPK 
mediates visfatin/PBEF/Nampt-induced proliferation in vascular 
smooth muscle cultures (Wang et al., 2009). Through its growth-
promoting properties for vascular smooth muscle, visfatin/PBEF/
Nampt emerges as a player in the development and progression of 
atherosclerotic lesions.
cEll aPoPtosIs and cEll surVIVal
As stated above, intracellular visfatin/PBEF/Nampt is acknowledged 
to play a central role in cell maturation and survival. Similarly, 
extracellular visfatin/PBEF/Nampt exerts anti-apoptotic effects and 
promotes cell survival. Thus, it has been demonstrated that visfatin/
PBEF/Nampt attenuates cell apoptosis induced by hydrogen perox-
ide in both human endothelial cells (Adya et al., 2008a) and rat vas-
cular smooth muscle cells in vitro (Wang et al., 2009). Importantly, 
visfatin/PBEF/Nampt promotes the survival of  macrophages 
FigurE 2 | Diagram summarizing the main reported actions of visfatin/
Nampt/PBEF in the cardiovascular system. The arrows indicate the potential 
clinical and therapeutical consequences of visfatin/PBEF/Nampt action (orange 
arrows, detrimental actions; green arrows, beneficial actions). Some of the 
actions of visfatin remain to date highly contradictory, such as its role in the 
regulation of the vascular tone.
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in different clinical conditions, including type 2 diabetes mellitus 
(Takebayashi et al., 2007) and chronic kidney disease (Yilmaz et al., 
2008). Conversely, the normalization of endothelial function fol-
lowing a renal transplantation is associated with a reduction in 
the circulating levels of visfatin/PBEF/Nampt (Yilmaz et al., 2009). 
These data suggest that, besides representing a potential biomarker 
for endothelial dysfunction and vascular damage, visfatin/PBEF/
Nampt might play a direct role in impairing vascular relaxation. 
Additional studies using both in vivo and in vitro approaches are 
therefore needed to clarify the capacity of visfatin/PBEF/Nampt to 
directly regulate the vascular tone.
might exert a vasorelaxant effect. Accordingly, it has been shown that 
the addition of visfatin/PBEF/Nampt to an organ bath results in the 
relaxation of isolated rat aortas pre-contracted with noradrenaline, 
through a mechanism that is independent of the insulin receptor 
(Yamawaki et al., 2009).
Nevertheless, Wang et al. (2009) could not demonstrate any 
contribution of visfatin/PBEF/Nampt on the regulation of the vas-
cular tone exerted by perivascular fat on rat aortas. Furthermore, 
a growing bulk of evidence shows a positive association between 
circulating visfatin/PBEF/Nampt levels and endothelial dysfunc-
tion, assessed by brachial artery flow-mediated dilation (FMD) 
FigurE 3 | Main signaling pathways that mediate visfatin/PBEF/
Nampt-induced endothelial cell proliferation and migration. Visfatin/PBEF/
Nampt promotes vascular endothelial growth factor (VEGF) synthesis and 
secretion and up-regulates the expression of the VEGF receptor 2. Visfatin/
PBEF/Nampt favors the endothelial production of nitric oxide (NO), a promoter of 
VEGF release, by activating endothelial nitric oxide synthase (eNOS) via the 
PI3K/Akt pathway. NO production is further enhanced through the activation of 
dimethylarginine dimethylaminohydrolase (DDAH), which degrades the eNOS 
inhibitor asymmetric dimethylarginine (ADMA). Additionally, visfatin/PBEF/
Nampt triggers the endothelial production of other pro-angiogenic molecules, 
such as monocyte chemoatractant protein (MCP)-1 and fibroblast growth factor 
(FGF)-2. On the other hand, visfatin/PBEF/Nampt enhances the levels and 
activation of matrix metalloproteinases (MMP)-2/9 while decreasing the levels of 
tissue inhibitor of metalloproteinases (TIMP)-1/2.
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action of visfatin/PBEF/Nampt is prevented by the pharmacological 
Nampt inhibitor APO866 and mimicked by NMN, the final product 
of the reaction catalyzed by Nampt (Romacho et al., 2009).
Visfatin/PBEF/Nampt can also contribute to vascular inflamma-
tion through its direct actions on monocytes. Hence, visfatin/PBEF/
Nampt promotes the synthesis and release of pro-inflammatory 
cytokines, such as tumor necrosis factor (TNF)-α and IL-8, by 
peripheral mononuclear cells (Dahl et al., 2007). As stated above, 
visfatin/PBEF/Nampt promotes macrophage survival (Li et al., 
2008), which may help perpetuating vascular inflammation.
Matrix metalloproteinases are pivotal enzymes mediating the 
degradation of extracellular matrix and facilitating atheroscle-
rotic plaque fragility and disruption. In endothelial cells (Adya 
et al., 2008b), but also in monocytes (Dahl et al., 2007), visfatin/
PBEF/Nampt induces the expression and activity of MMP-2 and 
MMP-9. Interestingly, an enhanced visfatin/PBEF/Nampt content 
has been detected in human unstable versus stable carotid plaque 
samples (Dahl et al., 2007). Furthermore, a positive association 
between visfatin/PBEF/Nampt and unstable atherosclerotic lesions 
is also found in patients with coronary artery disease (CAD) and 
acute myocardial infarction, with a strong visfatin/PBEF/Nampt 
immunostaining observed in lipid-rich regions at the site of plaque 
rupture (Dahl et al., 2007). Immunoreactive visfatin/PBEF/Nampt 
has also been detected in vascular smooth muscle cells within the 
atherosclerotic plaque (Spiroglou et al., 2010). Taken together, these 
findings suggest that visfatin/PBEF/Nampt can be a relevant mol-
ecule in plaque weakening.
Through its multiple actions promoting cytokine and chem-
okine secretion, macrophage survival, leukocyte recruitment by 
endothelial cells, vascular smooth muscle and endothelial cell 
inflammation and matrix degradation, visfatin/PBEF/Nampt, 
either circulating or locally synthesized, may contribute to the 
development of atherosclerotic lesions and plaque vulnerability 
and rupture. Visfatin/PBEF/Nampt is therefore gaining relevance 
as a potential therapeutic target to interfere with the inflammatory 
response associated to obesity-related complications, especially to 
atherosclerosis.
cardIac actIons
To date, only few reports have studied the direct effects of visfatin/
PBEF/Nampt on cardiac function, showing apparently opposite 
results. On one side, visfatin/PBEF/Nampt may be involved in the 
pathogenesis of myocardial fibrosis; on the other, visfatin/PBEF/
Nampt has been claimed to possess potential cardioprotective 
properties.
The proliferation of cardiac fibroblasts and the excessive accu-
mulation of extracellular matrix are at the basis of myocardial 
fibrosis. In vitro studies have recently shown that visfatin/PBEF/
Nampt promotes DNA synthesis and proliferation of cultured 
cardiac fibroblasts (Yu et al., 2010). The expression and protein 
levels of procollagen I and II are also elevated in cardiac fibrob-
lasts stimulated with visfatin/PBEF/Nampt, which ultimately leads 
to enhanced type I and III collagen release (Yu et al., 2010). The 
stimulation of cardiac fibroblasts by visfatin/PBEF/Nampt involves 
the activation of Akt/PKB and the MAP kinases p38 and JNK, but 
not ERK 1/2 (Yu et al., 2010). Taking into account that visfatin/
PBEF/Nampt is expressed in periadventitial and apical epicardial 
Vascular InflammatIon and athErosclErosIs
In the last years, a large number of reports have highlighted the pro-
inflammatory properties of visfatin/PBEF/Nampt on a wide range 
of cell types and tissues. As stated in the Introduction, PBEF was first 
identified as an immunomodulatory cytokine that synergizes with 
interleukin 7 (IL-7) and stem cell factor (SCF) to promote pre-B 
cell colony formation (Samal et al., 1994). Visfatin/PBEF/Nampt is 
now being regarded as a marker of inflammation. Serum visfatin/
PBEF/Nampt levels have been positively correlated with circulating 
inflammatory markers, such as IL-6, CRP and MCP-1 (Oki et al., 
2007; Kato et al., 2009; Liu et al., 2009a). Indeed, visfatin/PBEF/
Nampt levels are positively associated to a series of inflammatory 
conditions, including osteoarthritis, acute lung injury, inflamma-
tory bowel disease and Crohn’s disease, gynecological disorders, 
such as infection-induced pre-term birth, sepsis, or psoriasis 
(Moschen et al., 2010).
In the context of cardiovascular diseases, visfatin/PBEF/Nampt 
has been proposed as a marker of atherosclerosis, a clinical condi-
tion characterized by low-grade chronic inflammation (Liu et al., 
2009a; Kadoglou et al., 2010). Other studies, however, suggest that 
visfatin/PBEF/NAMPT may not directly reflect atherosclerotic 
changes, but rather the global inflammatory status in cardiovas-
cular and renal patients (Kato et al., 2009). Importantly, a positive 
correlation has been found between the expression of visfatin/
PBEF/Nampt in the periaortic and pericoronary fat and coronary 
atherosclerosis (Spiroglou et al., 2010), highlighting that perivas-
cular visfatin/PBEF/Nampt might play an important paracrine role 
in the development of atherosclerotic lesions.
In this context, a growing bulk of evidence indicates that vis-
fatin/PBEF/Nampt can directly promote vascular inflammation 
by activating different cell types including endothelial cells, vas-
cular smooth muscle cells, or monocytes/macrophages. Thus, in 
cultured human umbilical vein endothelial cells, visfatin/PBEF/
Nampt activates the inflammation-related transcription factor 
NF-κB (Kim et al., 2008; Adya et al., 2009; Lee et al., 2009) and 
promotes the expression of cell adhesion molecules, including 
ICAM-1, VCAM-1, or E-selectin (Kim et al., 2008; Lee et al., 
2009), as key molecules implicated in leukocyte recruitment and 
early pro-atherosclerotic events (Galkina and Ley, 2007). Visfatin/
PBEF/Nampt further promotes the endothelial release of several 
cytokines and chemokines by endothelial cells, including inter-
leukin (IL)-6, IL-8 or MCP-1 and its putative receptor CCR2 (Lee 
et al., 2009; Liu et al., 2009b), and thus promotes the adhesion of 
human THP-1 monocytes to endothelial cells (Liu et al., 2009b). 
The MAPK ERK 1/2 and p38, as well as PI3K and the intracel-
lular generation of reactive oxygen species, have been involved in 
endothelial cell inflammation induced by visfatin/PBEF/Nampt 
(Kim et al., 2008; Liu et al., 2009b).
In human vascular smooth muscle cell cultures, visfatin/PBEF/
Nampt consecutively activates ERK 1/2 and NF-κB, that in turn 
stimulates the expression of inducible nitric oxide synthase (iNOS) 
(Romacho et al., 2009), a NO- and peroxynitrite-forming pro-in-
flammatory enzyme playing a key role in vascular damage and 
endothelial dysfunction (Pacher et al., 2005). The pro-inflamma-
tory action of visfatin/PBEF/Nampt in human vascular smooth 
muscle cells is not mediated by the insulin receptor, but rather relies 
on Nampt intrinsic activity. Accordingly, the pro-inflammatory 
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